Aurora Cannabis Denies News of Acquisition of MedLeaf Therapeutics

Aurora Cannabis (NASDAQ: ACB) has officially denied rumors regarding its alleged acquisition of New Zealand-based MedLeaf Therapeutics.

Rhea-AI Summary

Aurora Cannabis (NASDAQ: ACB) has officially denied rumors regarding its alleged acquisition of New Zealand-based MedLeaf Therapeutics. The company explicitly stated it has not entered into any agreement with MedLeaf Therapeutics, nor has it engaged in any discussions about a potential business combination. The statement comes in response to incorrect information published on a news website. Aurora also noted that it had filed its Q4 and fiscal year 2025 financial statements and management's discussion and analysis earlier that day, with all relevant information available on the company's website and regulatory platforms SEDAR+ and EDGAR.

Argus Session date unavailable

-12.82% session move Open Argus

Details

News Market Reaction – ACB

The recorded move for ACB in the trading session of this news was -12.82%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NASDAQ | TSX: ACB

EDMONTON, AB, June 18, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, has become aware of misinformation posted on a news website, incorrectly stating that Aurora has agreed to acquire New Zealand based MedLeaf Therapeutics. The Company has not entered into any such agreement, has had no discussions with MedLeaf Therapeutics with respect to any business combination transaction, and has not made any statement or filed any information pertaining to any such transaction.

Earlier today before market open, Aurora filed the Company's financial statements and management's discussion and analysis for the fourth quarter and fiscal year ending March 31, 2025. All information pertaining to these disclosures is available on the Company's website at www.auroramj.com and on SEDAR+ and EDGAR.

About Aurora Cannabis

Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and New Zealand. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co., as well as international brands, Pedanios, Bidiol, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched. Learn more at www.auroramj.com and follow us on X and LinkedIn.

Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".

Forward Looking Information  

This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur.

These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the magnitude and duration of potential new or increased tariffs imposed on goods imported from Canada into the United States; the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses,  the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information form dated June 17, 2025  (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-cannabis-denies-news-of-acquisition-of-medleaf-therapeutics-302485728.html

SOURCE Aurora Cannabis Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Is Aurora Cannabis acquiring MedLeaf Therapeutics in 2025?

No, Aurora Cannabis has officially denied any acquisition of MedLeaf Therapeutics and stated they have had no discussions regarding any business combination.

What did Aurora Cannabis (ACB) announce on June 18, 2025?

Aurora Cannabis announced a denial of rumors regarding an acquisition of MedLeaf Therapeutics and noted the filing of their Q4 and fiscal year 2025 financial statements.

Where can investors find Aurora Cannabis (ACB) financial statements for fiscal year 2025?

Aurora's fiscal year 2025 financial statements are available on the company's website (www.auroramj.com), SEDAR+, and EDGAR.

Has Aurora Cannabis had any discussions with MedLeaf Therapeutics about an acquisition?

No, Aurora Cannabis explicitly stated they have had no discussions with MedLeaf Therapeutics regarding any business combination transaction.